Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3231-3244
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3231
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3231
Table 2 Proteomics biomarker candidate studies and main findings
Ref. | Sample | Analysis | Findings and perspectives |
Barcelo-Batllori et al[66], 2002 | In vitro colon epithelial cells and purified epithelial cells from UC and CD patients | 2D-PAGE protein quantitation, and in-gel digestion and MALDI-TOF MS and Western blot protein identification | The enzyme indoleamine-2,3-dioxygene was more abundant in cells from CD and UC patients compared to normal mucosa. Tryptophan and arginine metabolism may play a role in the IBDs |
Hardwidge et al[67], 2004 | Human Caco-2 intestinal epithelia cells before and after infection with E. coli | ESI LC-MS protein identification and quantitation, Western blot verification | 125 proteins more abundant and 139 proteins less abundant after infection, some related to innate immune responses. These proteins might be relevant to look for in future biomarker studies |
Hsieh et al[68], 2006 | Colonic biopsies from UC, nonspecific infectious colitis patients and controls | 2D-PAGE protein quantitation, and in-gel digestion and MALDI-TOF MS protein identification | 6 proteins were found to be more abundant in UC and 13 less abundant. The result indicates that mitochondrial dysfunction might be involved in UC the etiology. Four biomarker candidates were identified, however, they require validation |
Shkoda et al[69], 2007 | Intestinal tissue cells purified from patients suffering from CD, UC, and colon cancer | 2D-PAGE protein quantitation, and in-gel digestion and MALDI-TOF MS and Western blot identification | Proteins associated with signal transduction, stress response and energy metabolism were differently abundant in inflamed and non-inflamed tissue. 32% of the differentially regulated proteins were involved in energy metabolism |
Meuwis et al[10], 2007 | Serum from UC and CD patients | SELDI-TOF MS m/z signal profiling, MALDI-TOF MS and Western blot protein identification | Successful in differentiating CD from UC patients with a sensitivity of 85% and a specificity of 95% from several m/z signals. Four biomarker candidates were identified, all known acute inflammatory markers, limiting the diagnostic value. However, the feasibility of serum biomarker studies was demonstrated |
Nanni et al[71], 2007 | Serum from UC, CD patients and healthy controls | Solid-phase bulk protein extraction, MALDI-TOF MS signal profiling | Able to separate the three groups with 97% prediction results. The signals were not identified, but the feasibility of serum biomarker studies was demonstrated |
Meuwis et al[70], 2008 | Serum from responding and non-responding CD patients to infliximab | SELDI-TOF MS signal profiling, MALDI-TOF MS, Western blot and ELISA protein identification | Able to predict responders with a sensitivity of 79% and a specificity of 80%. Increased amount of PF4 was associated with non-response to infliximab with MS but not ELISA, so usability of PF4 as a biomarker seems limited |
Nanni et al[72], 2009 | Intestinal epithelial cells from CD patients and healthy controls | 1D-PAGE and in-gel digestion, ESI LC-MS protein identification and quantitation | Proteins more abundant in CD patients include several proteins involved in inflammation processes, and less abundant include Annexin A1, involved in the anti-inflammatory action. Follow-up research is required to assess the feasibility of the biomarker candidates |
Hatsugai et al[73], 2010 | Peripheral blood mononuclear cells from UC and CD patients, and healthy controls | 2D-PAGE quantitation, and in-gel digestion and MALDI-TOF MS protein identification | Successfully discriminated UC from CD based on seven differently present proteins, all associated with inflammation oxidation/reduction, the cytoskeleton, endocytotic trafficking and transcription.The biomarker candidates require validation using a larger number of patients, but seems promising |
M’Koma et al[74], 2011 | Mucosal and submucosal layers of samples originating from CC and UC patients | MALDI-TOF MS m/z signal characterization, no protein identification | Five m/z signals were detected in the submucosal layer, which could separate the two groups with an accuracy of 75 percent. The signals needs to be identified, however, the disease groups can be separated on basis of the mucosal and submucosal profiles |
Presley et al[75], 2012 | Microbes and human proteins at the intestinal mucosal-luminal interface from CD and UC patients, and healthy controls | Oligonucleotide ribosomal RNA fingerprinting, SELDI-TOF MS and MALDI-TOF MS identification | 35% of the detected bacterial phylotypes were present in different amounts in the diseases, indicating the involvement of host-microbe interactions in IBD. The microbiome might prove useful as a target for therapy |
Han et al[14], 2013 | Colonic tissue biopsies of Korean IBD patients | ESI LC-MS protein identification with label-free quantitation | 27 potential biomarkers were identified for UC, 37 biomarkers for CD and 11 proteins commonly associated with IBD. Three novel biomarkers were identified for active CD: Bone marrow proteoglycan, L-plastin and proteasome activator subunit 1. The biomarker candidates require validation, but might prove feasible as new diagnostic and therapeutic targets |
Seeley et al[76], 2013 | Histological tissue layers from UC and CC patients | MALDI-TOF MS m/z signal characterization, no protein identification | 114 different m/z signals were found to be different between the two groups. The signals remain unidentified |
Gazouli et al[77], 2013 | Serum samples from responding and non-responding CD patients to infliximab treatment | 2D-PAGE quantitation, and in-gel digestion and MALDI-TOF MS protein identification | 15 differently abundant proteins between responders and non-responders to infliximab were identified.The biomarker candidates require further validation |
- Citation: Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies. World J Gastroenterol 2014; 20(12): 3231-3244
- URL: https://www.wjgnet.com/1007-9327/full/v20/i12/3231.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i12.3231